|
Destiny Pharma PLC - Brighton, England-based clinical-stage biotechnology - Gets 33% take-up of open offer of shares, raising £340,000. Destiny raises £7.3 million gross in total from the open offer, plus a share placing and subscription, all at 35 pence per share. Net proceeds are £6.7 million, which will be used to support a collaboration agreement in the US with Sebela Pharmaceuticals for NTCD-M3, Destiny’s lead asset for the prevention of clostridioides difficile infection recurrence. Current stock price: 32.50p 12-month change: down 37% Copyright 2023 Alliance News Ltd. All Rights Reserved.
|
